Treatment with the sodium–glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, attenuates progression of kidney disease and reduces the risks of heart failure and death in patients with chronic kidney disease (CKD). Data on the effects of dapagliflozin on health-related quality of life (HRQoL) are limited in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Heerspink et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: